Pharmaceutical

Biocytogen and Myricx Bio partner for development of ADCs

Biocytogen and Myricx Bio have signed an antibody evaluation, option and licence agreement for the development of ADCs.

Sep 9, 2023 - 20:00
Biocytogen and Myricx Bio partner for development of ADCs
Biocytogen and Myricx Bio have signed an antibody evaluation, option and licence agreement for the development of ADCs.
Read the original article

Tags:

Previous Article

EC expands indication approval for Merck’s Ebola vaccine

Next Article

Subcutaneous drugs grant a new lease on life to checkpoint inhibitors

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Moderna-Merck mRNA cancer vaccine shows promise in combination with melanoma drug

STAT+: Moderna-Merck mRNA cancer vaccine shows promise ...

Apr 17, 2023

ChromaDex wins orphan designation for rare ataxia drug

ChromaDex wins orphan designation for rare ataxia drug

Jun 8, 2024

AstraZeneca reports positive Phase III results for Imfinzi in small cell lung cancer

AstraZeneca reports positive Phase III results for Imfi...

Apr 7, 2024